Carbon monoxide may enhance bile secretion by increasing glutathione excretion and Mrp2 expression in rats  by Chen, Chiung-Yu et al.
Available online at www.sciencedirect.comJournal of the Chinese Medical Association 76 (2013) 258e264
www.jcma-online.comOriginal Article
Carbon monoxide may enhance bile secretion by increasing glutathione
excretion and Mrp2 expression in rats
Chiung-Yu Chen a, Chi-Ya Kao b, Po-Ju Lin b, Shu-Chu Shiesh b,*
aDepartment of Internal Medicine, National Cheng Kung University, Tainan, Taiwan, ROC
bDepartment of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Tainan, Taiwan, ROC
Received July 27, 2012; accepted September 21, 2012AbstractBackground: Nitric oxide (NO) donors have been reported to induce choleresis via an increased excretion of glutathione. The effects of another
gas molecule, carbon monoxide (CO), on bile formation are, however, inconsistent among previous reports. We investigated the sequential
changes of bile output and the biliary contents in rats with or without CO supplementation to elucidate the mechanism of CO on bile excretion.
Methods: Dichloromethane (DCM) was gastrically fed to male SpragueeDawley rats to yield CO by liver biotransformation. The rats were
divided into DCM-treated (n ¼ 7), DCM plus L-NAME-treated (n ¼ 6), and corn oil-treated-(n ¼ 8) groups. Bile samples were collected hourly
to examine the flow rate and bile content. Serum levels of nitrite and nitrate 4 hours after DCM supplementation with or without NO synthase
(NOS) inhibition were measured by capillary electrophoresis. The expression of hepatic inducible NOS was evaluated by Western blotting 6
hours after DCM administration.
Results: Levels of carboxyhemoglobin rose to around 10% at 4 hours after DCM supplementation and were maintained until the end of the
experiments. Bile flow increased after DCM supplementation and was associated with a concomitant increase of biliary glutathione and higher
hepatic multidrug resistance-associated protein 2 (Mrp2) expression. Hepatic inducible NOS expression and serum nitrate/nitrite levels were also
increased. Treatment with an NOS inhibitor (L-NAME) abolished the CO-induced glutathione excretion and choleresis, but not Mrp2
expression.
Conclusion: The present study demonstrated that CO enhanced biliary output in conjunction with NO by increasing the biliary excretion of
glutathione. The increment in biliary glutathione was associated with an increased expression of hepatic Mrp2.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Carbon monoxide (CO) is well-known for its toxicity at
high concentrations; however, blood levels of carbox-
yhemoglobin (COHb) below 20% are well tolerated in humans
and are considered as the “biological threshold”.1 Extensive
evidence examining large and small animals has shown the
beneficial effects of CO in cardiovascular disease, sepsis and* Corresponding author. Prof. Shu-Chu Shiesh, Department of Medical
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University Road, Tainan 701, Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2013.02.001shock, cancer, transplantation, and acute lung, kidney, and
liver injury.2 The first randomized, placebo-controlled phase I
trial to use inhaled CO in healthy subjects has recently been
completed using the Covox DS delivery device (Ikaria,
Hampton, NJ, USA).3
The effects of CO on bile excretion are, however, incon-
sistent among previous studies. Abolishing CO from the
perfused liver led to an increase in bile acid-dependent bile
flow, indicating a negative effect of CO on bile formation.4
However, other studies have demonstrated that CO enhanced
bile excretion by inducing bilirubin and glutathione (GSH)5 or
bicarbonate excretion.6 Similar to CO, the gaseous signal
molecule nitric oxide (NO) also modulates the formation ofhinese Medical Association. All rights reserved.
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increasing biliary GSH excretion.7 As CO has been reported to
induce NO production,8 CO may therefore enhance bile
excretion through the action of NO.
The customary bile output in healthy subjects ranges from
500 mL to 700 mL a day. Such between-subject variations in
bile excretion may be also present in animals and cause dif-
ficulties in comparing bile output after different treatments.
Moreover, CO also acts on other organs including the car-
diovascular system, lung, kidney, and intestine.2 However,
using a liver perfusion (i.e., ex vivo) model may not reflect the
effect of CO on bile formation under physiologic conditions.
As a consequence, an examination of sequential changes in
bile output and biliary contents in the same animal pre- and
post-CO administration would be more relevant to investigate
the in vivo effects of CO on bile excretion.
Dichloromethane (DCM) is oxidized by liver cytochrome
P450 to yield CO and carbon dioxide.9 A mean maximum
COHb level of 9.3% was detected in rats 6 hours after a single
oral dose of DCM (6.2 mmol/kg) with a protective effect
against immune-mediated liver damage.10
Bile formation is an osmotic process driven by the active
transport of solutes into the bile. Water moves from blood into
bile in response to osmotic gradients.11,12 Membrane trans-
porters such as multidrug resistance-associated protein 2
(Mrp2) are responsible for regulating the uptake and excretion
of various biliary solutes.13,14 By examining the sequential
changes in biliary content, bile output, hepatic inducible NO
synthase (iNOS), and Mrp2 expression in DCM-fed rats, we
aimed to investigate the effect of CO on bile output and its
underlying mechanism.
2. Methods2.1. Experimental animals and proceduresMale SpragueeDawley rats, each weighing 270e300 g,
were used. After injection of 1 mL/kg of Zoletil 50 (Virbac,
Carros, France) intraperitoneally for anesthesia, a midline lap-
arotomy was performed. The common bile duct was explored
and a tiny hole was created over its middle part. Through this
hole, a PE 10 polyethelene tube (0.011 inch inner diameter,
0.024 inch outer diameter; Clay Adams, Parsippany, NJ, USA)
was inserted. The PE 10 tube and the common bile duct were
then tied togetherwith 4-0 silk at both ends of the insertion site to
prevent bile leakage. Finally, the PE 10 tube was connected to a
light-shielded Eppendorf tube for bile collection. For gastric
feeding, a plastic tube (the extension tube of an infusion set, 12
inch; SigmaMedical Supplies, Taipei, Taiwan)was inserted into
the stomach via an incision made over the anterior wall of the
stomach. The abdominal wall was closed in layers after
completing the above surgical procedures.
DCM (6.2 mmol/kg; Sigma Chemical Co., St. Louis, MO,
USA) in corn oil, or corn oil alone was infused into the rats’
stomachs via a gastric tube. To investigate the interaction of
NO and CO, a dose of 30 mg/kg of the NOS inhibitor Nu-
nitro-L-arginine methyl ester (L-NAME; Sigma Chemical Co.)was injected into the peritoneal cavity 1 hour after gastric
feeding of DCM. Thereafter, the rats were divided into a
DCM-fed group (DCM group, n ¼ 7), a corn oil-fed group
(control group, n ¼ 8), and a DCM-fed plus L-NAME-treated
group (L-NAMEeDCM group, n ¼ 6).
During the experiment, anesthesia was maintained with
supplemental bolus injections of ketamine (30mg/kg)when any
spontaneous muscle activity or lessening of the anesthetic plane
occurred. Bile was collected hourly for 7 hours. A volume of
1 mL of 5% glucose was administered every hour via the gastric
tube to avoid dehydration and starvation in the rats. When the
experiment concluded, the rats were sacrificed by anesthesia
overdose. The liver was harvested after portal venous perfusion
with phosphate buffer solution, and blood was drawn from the
abdominal aorta. The protocol was approved by the Animal
Care and Use Committee at our university, and all animals
received care according to the animal center’s regulations.2.2. Measurement of hepatic iNOS expression and NO
productionTo study whether CO induces NO production, the rats were
fedwithDCM (6.2mmol/kg) in corn oil (n¼ 7) or corn oil alone
(n¼ 6) as described above and were sacrificed at the 4th hour of
the experiment. Induction of NOwas assessed by examining the
expression of iNOS in liver extract and serum levels of nitrate
and nitrite. The expression of iNOS was determined byWestern
blotting on 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) using antibody to inducible NOS
(1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Serum samples were pretreated by Microcon YM-3 ultrafiltra-
tion devices (Millipore Corporation, Bedford, MA, USA), and
serum levels of nitrite and nitrate were measured by a high-
performance capillary electrophoresis system (P/ACE MDQ;
Beckman Coulter, Fullerton, CA, USA) with an ultraviolet de-
tector set at 214 nm. The imprecision of themethodwas less than
8.5%, and the mean recovery was 115% (range 112.8e119.3%,
n ¼ 3).2.3. Measurement of COHbBlood levels of COHb were measured 1, 2, 4, and 6 hours
after gastric feeding by sampling blood from the retro-orbital
plexus of a rat with or without DCM treatment and from the
abdominal aorta at sacrifice. A Co-Oximeter IL-1725
(Instrumentation Laboratories, Lexington, MA, USA) was
used to measure COHb levels.2.4. Measurement of bile output and biliary solutesBile output was determined gravimetrically, assuming a
density of 1.0 g/mL. Biliary bicarbonate concentration and pH
were measured immediately by a blood gas analyzer (IL
Synthesis-25; Instrumentation Laboratories). Bile samples
were centrifuged at 7000 rpm for 10 minutes, and the super-
natants were stored at e8C until analysis. For GSH mea-
surement, bile samples were treated with 10% trichloroacetic
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7000 rpm for 10 minutes. The supernatant was aspirated to
analyze reduced and oxidized GSH.
High-performance liquid chromatographyetandem mass
spectrometry was used to quantitate the GSH as previously
described.15 The chromatographic separation was performed
at 45C using a MS C18 column (2.1 mm  150 mm, 3.5 mm
particle size; Waters, Milford, MA, USA). The mobile phase
consisted of 0.1% acetic acid in (1) H2O and in (2) acetonitrile
at a flow rate of 300 mL/min. The transitions m/z (Q1 to Q3)
for GSH, GSH disulfide (GSSG), and internal standard,
respectively, were 308.4/162.3, 613.7/354.8, and 311.4/181.8
on an API 5000 tandem mass spectrometer (Sciex, ON, Can-
ada). The TCA-treated bile was mixed with 1:10 volume of the
internal standard (glycine-13C2,
15N). The filtered supernatant
was used for GSH quantification. The method was linear over
a range of 5e5000 ng/mL with a correlation coefficient (r)
greater than 0.99. The intrarun imprecision was less than 5%
at the mean levels of 339 and 1758 ng/mL, and the interrun
was less than 9%. The average recovery of GSH and GSSG
was 104.8% and 123.5%, respectively.
Total bile acids were determined by an enzymatic method
(Bio-Quant, San Diego, CA, USA) using 3-a-hydroxysteroid
dehydrogenase. In the presence of thio-NAD, this enzyme
converts bile acid to 3-keto steroids and thio-NADH. The
amount of thio-NADH formed was measured at 405 nm.
Bilirubin was measured by a diazo method on the Modular DP
analyzer (Roche Diagnostics, Mannheim, Germany).
Sequential changes in bile output and biliary contents were
expressed in relative fold changes, compared to those levels at
the first hour. Differences in bile output and biliary contents
between rats receiving corn oil, DCM, or DCM plus L-NAME
treatment were compared at hourly intervals and in total by
calculating the area under the curve (AUC).2.5. Measurement of liver Mrp2 expressionProtein concentration was determined by the bicinchoninic
acid protein method (Pierce Biotechnology, Rockford, IL,Fig. 1. Blood levels of carboxyhemoglobin (COHb) of experimental rats (A) from
end of the experiment in DCM-treated, corn oil-treated, and L-NAME plus DCM-USA) using albumin as a standard. Western blot analysis was
carried out with 50 mg protein of liver homogenates per well
on 8% SDS-PAGE. After electrophoresis, the proteins were
transferred onto a polyvinylidene difluoride membrane for 1.5
hours at 100 V. The membranes were then blocked with 5%
milk/TBSe0.1% Tween solution and incubated with primary
antibodies to Mrp2 (1:2,000; Alexis Biochemicals, San Diego,
CA, USA) or b-actin (1:5000; Sigma Chemical Co.). After
washing, the membrane was incubated with horseradish-
peroxidase-coupled anti-mouse (1:50,000) or anti-rabbit IgG
(1:5,000) antibodies at room temperature for 1 hour. Immu-
noreactive bands were visualized using enhanced chem-
iluminescence Western blotting detection reagents (Pierce
Biotechnology) on a luminescent image analyzer LAS-3000
(Fujifilm Life Science, Stamford, CT, USA). Western blot
analysis was repeated twice to confirm the initial results.2.6. Statistical analysisData are expressed as mean  standard error of the mean.
The differences between groups were analyzed by Man-
neWhitney U test using GraphPad Prism 5.0 (GraphPad
Software, La Jolla, CA, USA). A p value less than 0.05 was
considered as significant.
3. Results3.1. Blood COHb after DCM treatmentBlood COHb was around 3% at the basal level in both the
control and DCM groups and began to rise in DCM-fed rats at
2 hours after DCM feeding (Fig. 1A). As shown in Fig. 1A and
1B, COHb was significantly increased at 4 hours after DCM
treatment, reached a peak level (12%) at 6 hours, and persisted
at this level until the end of the experiment (11.2  0.7% at 7
hours). Treatment with L-NAME did not affect the biotrans-
formation of CO from DCM, and the mean level of COHb in
this group rats was 12.1  1.3% at 7 hours post DCM feeding
(Fig. 1B). Blood COHb in the control group did not change,1 hour to 6 hours after dichloromethane (DCM) administration, and (B) at the
treated groups.
Fig. 2. Effects of dichloromethane (DCM) on (A) hepatic expression of inducible nitric oxide synthase (iNOS), and (B) serum levels of nitrite/nitrate (NOx) in rats
4 hours after treatment.
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(Fig. 1B).3.2. CO-induced iNOS expression and NO productionExpression of iNOS was significantly higher in the liver
homogenates of rats at 4 hours after DCM treatment compared
to those of the control group (2.62  0.07 vs. 1.98  0.18;
p ¼ 0.007) (Fig. 2A). As shown in Fig. 2B, serum levels of
nitrate and nitrite were significantly higher in the DCM group
than the control group (224.0  17.1 mmol/L vs.
165.6  19.8 mmol/L; p ¼ 0.03).3.3. Changes in bile output by COAs shown in Fig. 3A, the bile output of DCM-fed rats
increased significantly compared to that of the control group
(AUC 10.12  0.69 vs. 6.77  0.21; p < 0.001). L-NAME
treatment abolished the choleretic effect of DCM (AUC for the
L-NAMEeDCM group vs. the DCM group 6.62  0.20 vs.
10.12  0.69; p ¼ 0.008).Fig. 3. Sequential changes in (A) bile output and (B) total glutathione excreti
DCM-treated groups. *p < 0.05, **p < 0.01, ***p < 0.001 between DCM- and
L-NAME plus DCM-treated rats.3.4. Changes of biliary contents by COAs demonstrated in Fig. 3B, there was a significant increase
in total glutathione (GSH þ GSSG) excretion at 4 hours after
DCM treatment (AUC for the DCM group vs. the control
group 7.56  1.34 vs. 4.39  0.35; p ¼ 0.035). The increase in
GSH excretion in DCM-fed rats was diminished with L-
NAME treatment (AUC for the L-NAMEeDCM group
4.17  0.30; p ¼ 0.026).
As shown in Fig. 4A, CO did not alter the excretion of
biliary bicarbonate (AUC for the DCM group vs. the control
group 5.07  0.12 vs. 5.41  0.26; p ¼ 0.174). However, the
biliary excretion of bicarbonate showed a decline from the
basal level until 7 hours in both the DCM and control groups.
The decrement was significantly lessened in DCM-fed rats
with L-NAME treatment (AUC for the L-NAMEeDCM group
5.78  0.22; p ¼ 0.008).
Bile acid excretion decreased in all experimental rats, with
biliary bile acids at 7 hours less than half of the initial levels
(Fig. 4B). Similar to the changes in biliary excretion of bi-
carbonate, the decrement was lessened significantly in
DCM-fed rats with L-NAME treatment (AUC for theon in dichloromethane (DCM)-treated, corn oil-treated, and L-NAME plus
corn oil-fed rats; #p < 0.05, ##p < 0.01, ###p < 0.001 between DCM- and
Fig. 4. Sequential changes in (A) bicarbonate, (B) total bile acids, and (C) total bilirubin excretion in dichloromethane (DCM)-treated, corn oil-treated, and L-
NAME plus DCM-treated groups. #p < 0.05, ##p < 0.01 between DCM- and L-NAME plus DCM-treated rats.
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2.45  0.12; p ¼ 0.026).
Excretion of biliary bilirubin increased in all experimental
rats with no significant difference among the different exper-
imental groups (Fig. 4C; AUC for the control, DCM, and
L-NAMEeDCM groups 10.45  0.99, 8.40  0.49, and
10.89  1.15, respectively).Fig. 5. Effects of dichloromethane (DCM) with or without nitric oxide syn-
thase inhibitor (L-NAME) on Mrp2 expression.3.5. Hepatic Mrp2 expressionAs shown in Fig. 5, DCM treatment significantly increased
hepatic Mrp2 expression (DCM group vs. control group
0.30 0.04 vs. 0.15 0.01; p¼ 0.002).Although the expression
of hepatic Mrp2 tended to decrease after L-NAME treatment,
this was not statistically significant (L-NAMEeDCM group vs.
DCM group 0.22  0.01 vs. 0.30  0.04).4. Discussion
Our study demonstrates that biliary excretion was
increased by CO at physiologically relevant concentrations.
The choleretic effect of CO was caused by an increased
excretion of total glutathione, which was associated with an
enhanced expression of Mrp2. In addition, CO induced NO
production; the inhibition of NO reduced the total glutathione
excretion and diminished the choleretic effect of CO. NO,
therefore, plays a role in the mechanism of CO-induced
choleresis.
Sano et al, using zinc protoporphyrin IX to inhibit heme
oxygenase (HO) and thereby abolishing CO in the venous
perfusate, reported that bile acid-dependent bile output was
increased by CO suppression.4 Their results indicated that CO
exerted a negative effect on bile formation.4 However, two
studies demonstrated that CO enhanced biliary output.5,6 The
controversies relating to the effect of CO on bile excretion
may be attributed to the fact that CO regulates bile excretion
biphasically in a dose-dependent manner. CO causes choler-
esis at a concentration of 4 mM, while higher concentrations of
CO increase paracellular junctional permeability, decrease the
263C.-Y. Chen et al. / Journal of the Chinese Medical Association 76 (2013) 258e264biliary excretion of bile acids, and abolish the choleretic effect
of CO.5 Our findings were consistent with those reports that
CO induces choleresis at physiologically relevant
concentrations.5,6
Bile is formed primarily by osmotic filtration resulting
from active transport of biliary solutes.16 Among the biliary
contents, bile acids,13 GSH (oxidized or reduced),17 and
perhaps bicarbonate18 meet the criteria. HO catalyzes the
degradation of heme to yield biliverdin, iron, and CO.19 By
intraperitoneal injection of hemin to induce HO-1, Shintani
et al demonstrated that CO suppressed hydrogen sulfide
generation and stimulated biliary output and bicarbonate
excretion in mice.6 However, by transportal administration
of 4 mM of CO to perfused rat liver, Norimizu et al showed
that CO increased biliary excretion of GSH and resulted in
choleresis.5
Several factors may underlie the controversial results from
the CO studies. First, the amount of CO induced by HO-1 is
unknown, and CO has been shown to act differently on
biliary excretion at different concentrations.5 Second, the
induction of HO-1 increases the concentrations of biliverdin,
iron, and CO; the effect of CO alone on bile excretion is
difficult to assess. Third, different species of animal (rats vs.
mice) or experimental models (in vivo vs. ex vivo) were used
and may cause variations among studies. Instead of HO-1,
the present study used DCM to generate CO specifically,
and the results indicate that the choleretic effect of CO on
rats was caused by an increase in biliary total glutathione
excretion.
GSH is mainly synthesized in the liver, and is excreted into
bile in both its reduced and its oxidized forms.17 A high-
affinity electrogenic canalicular carrier and MRP2 that
actively export both oxidized and reduced GSH into bile have
been functionally characterized.20,21 Our study showed that
CO enhanced biliary output by increasing Mrp2 expression in
rat liver, and hence biliary excretion of GSH. This finding was
in accordance with that of Norimizu et al demonstrating that
the choleretic effect of CO was abolished in mice genetically
deficient for Mrp2.5
The gas molecules CO and NO are linked in that NO
upregulates HO-1 expression and leads to the formation of
endogenous CO,22 whereas CO induces NO production
through upregulation of nuclear factor-kB and iNOS.23
Exogenous NO has been reported to induce choleresis in
perfused rat liver by stimulating GSSG excretion, which is
independent of guanosine 30,50-cyclic monophosphate.7 Our
study showed that CO induced hepatic iNOS expression and
elevated biliary nitrate/nitrite levels. Although the expres-
sion of Mrp2 was mildly attenuated, the GSH excretion as
well as the choleretic effect of CO was completely abolished
by NOS inhibition. Infusion of nonspecific NO inhibitor
reduces NO production and decreases hepatic perfusion,
indicating that NO has a role in the liver microcirculation.24
Other than the effects on Mrp2 expression and GSH
excretion in our study, the reduced hepatic perfusion after
the injection of nonspecific NOS inhibitor demonstrated that
NO may have additional effects on the reduction of bileoutput. Despite the complex effects of CO and NO, our
findings suggest that NO contributes at least in part to the
CO-induced choleresis.
In addition to the liver, the exogenous application of low
doses of CO exerts protective effects on the lung, intestine,
blood vessels, heart, and kidney.2 In vivo studies, using animal
models similar to ours, are able to investigate the systemic
effects of CO and evaluate the effect of CO on bile excretion
under specific physiologic conditions. We examined sequen-
tial changes in bile output and biliary contents in the same rat
before and after CO administration instead of observing
changes in different rats at fixed intervals. Our results,
therefore, may be more relevant to investigations of the ac-
tions of CO on biliary excretion than previous studies have
been.
As the armamentarium of CO-releasing molecules now
continues to grow and expand, CO has become easier and
safer to administer. Our results indicate that CO would be a
therapeutic strategy for cholestatic diseases caused by down-
regulation of Mrp2, such as inflammation-induced chole-
stasis.25 However, further studies are needed to reveal how CO
acts with NO on bile excretion and how CO upregulates Mrp2.
In conclusion, our study demonstrates that CO upregulates
hepatic Mrp2 expression and induces NO formation. In
conjunction with the action of NO, CO increases biliary
excretion of GSH to produce the choleretic effect.References
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